Pharmaceutical Executive
If policy makers crafting a Medicare pharmacy benefit are worried about heavy prescription spending by seniors, they should take a closer look at medication use by the five million disabled beneficiaries in the program of 40 million patients.
If policy makers crafting a Medicare pharmacy benefit are worried about heavy prescription spending by seniors, they should take a closer look at medication use by the five million disabled beneficiaries in the program of 40 million patients. Medicare provides healthcare coverage for individuals under 65 who are totally and permanently disabled. Many qualify for Medicaid pharmacy benefits, but their low incomes make paying for prescription medicines particularly burdensome, according to a report on "Medicare's Disabled Beneficiaries: The Forgotten Population in the Debate Over Drug Benefits" from the Commonwealth Fund and the Henry J. Kaiser Family Foundation. That population fills more prescriptions and spends more on medicines each year than the elderly. (See "The Other Medicare Patients.")
The Other Medicare Patients
Moreover, the report points out, disabled Medicare beneficiaries use a different mix of pharmaceuticals than seniors do. Most notable is the heavy use of psychotherapeutics and analgesics -both low on the list of drugs commonly used by Medicare patients. (See "One Program, Two Lists.")
One Program, Two Lists
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.